NLRP3 and COVID-19: This is because melatonin inhibits NLRP3-mediated inflammation as well as other inflammatory effects derived from the inflammasome, inducing a systemic anti-inflammatory response, especially after severe inflammation [157], so it is expected that the inhibition of NLRP3 using melatonin may lead to a reduction in systemic inflammation and oxidative stress, and in so doing reducing the severe phenotypes in COVID-19 patients.